- Wheeler Bio has announced a strategic partnership with Mitsubishi Corporation to expand its business development and commercial reach across the Asia-Pacific region.
- The partnership includes Mitsubishi’s investment in Wheeler’s Series A-1 financing and focuses on connecting APAC biotech companies with Wheeler’s U.S.-based cGMP manufacturing capabilities.
Wheeler Bio, a U.S.-based contract development and manufacturing organization (CDMO), has entered a strategic partnership with Mitsubishi Corporation to strengthen its business development activities and commercial reach across the Asia-Pacific region.
As part of the agreement, Mitsubishi Corporation will invest in Wheeler’s Series A-1 financing and act as its exclusive commercialisation partner in the region. The company will leverage its extensive industry network and commercial expertise to identify and engage biotech innovators in Japan, South Korea, India, Singapore, Taiwan and China that seek U.S. development and cGMP manufacturing support.
The collaboration aims to connect these innovators to Wheeler Bio’s AI/ML-enabled ModularCMC™ platform and state-of-the-art biomanufacturing facility in Oklahoma City. The platform is designed to streamline the path from discovery to clinical development for antibody-based therapeutics, offering scalability and speed through its High-Touch, science-driven approach.
“We have long been engaged in the pharmaceutical CDMO market, and we are firmly convinced that Wheeler Bio’s service offerings will provide significant value to clients. Through this strategic partnership, we are confident that the development of biopharmaceutical seeds in the APAC region will be accelerated, ultimately contributing to the improvement of people’s lives.”
Takahiro Tokuda, Healthcare Division COO at Mitsubishi Corporation
“Wheeler is honoured to have Mitsubishi invest in and partner with Wheeler Bio in support of our business development efforts as we scale the organization. Mitsubishi’s long-term domain experience in biologics contract manufacturing is invaluable to our growth objectives.”
Patrick Lucy, President and CEO of Wheeler Bio
